Fig. 3: Effects of virologic rebound on each of the study outcomes. | Nature Communications

Fig. 3: Effects of virologic rebound on each of the study outcomes.

From: SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study

Fig. 3

A All patients. Cohort with virologic rebound (n = 1573) and cohort without virologic rebound (n = 12,322). B nirmatrelvir/ritonavir recipients. Cohort with virologic rebound (n = 417) and cohort without virologic rebound (n = 3542). C Molnupiravir recipients. Cohort with virologic rebound (n = 559) and cohort without virologic rebound (n = 3943). Adjusted HRs (square dots) and 95% CIs (error bars) are presented in (A–C). Adjustments were made for baseline covariates, including age, sex, Charlson Comorbidity Index, immunocompromised status, intensive care unit admission, concomitant treatments, ventilation support, COVID-19 vaccination status, the week of the index date, the initial Ct value at the index date, and the duration between the first and the last Ct measurement. The dashed vertical line in (A–C) represents the HR of 1.00. Statistical analysis with two-sided Wald test in (A–C). VR virologic rebound, CI confidence interval.

Back to article page